Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Easy to administer

Convenient once-daily intravenous (IV) dosing without dose adjustment1

Single loading dose: IV anidulafungin 200 mg
Daily maintenance dose: IV anidulafungin 100 mg

Duration of treatment should be based upon the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture1

No dose adjustments required:1
 

    •     in patients with mild, moderate or severe hepatic impairment
    •     in patients with any degree of renal insufficiency, including those on dialysis
    •     based on gender, weight, ethnicity, HIV positivity or in advanced age

Simple IV Preparation1

Ecalta® is easy to reconstitute:

    •     Choose a diluent: 0.9% saline or 5% glucose for infusion

Full preview Singe IV preparation

1. Reconstitute 

Reconstitute with 30ml WFI to provide a concentration of 3.3mg/ml

2. Mix

Allow up to 5 minutes for a clear solution free from visible particulates.

3. Dilute

Tranfer to an IV bag (or bottle) containing either 0.9% sodium chloride for infusion or 50mg/ml (5%) glucose for infusion, obtaining an anidulafungin concentration of 
0.77mg/ml

Ecalta® is easy to dilute:

Ecalta® is easy to administer:

    •     For IV use only
    •     Infusion rate should not exceed 1.1 mg/min (equivalent to 1.4 ml/min)

For more information, please refer to the full Summary of Product Characteristics.

Drug interactions

Ecalta® has no known drug interactions and it is not an inhibitor, inducer or substrate of CYP450 isoenzymes.1,2*

Ecalta (anidulafungin) No known drug interactions1*
Caspofungin3 Ciciosporin A, tacrolimus and rifampicin. Potential interaction with other inducers of metabolic enzymes such as efavirenz, dexamethasone, phenytoin, nevirapine and carbamazepine
Micafungin4 Itraconazole, sirolimus, nifedipine and amphotericin B deoxycholate 
Fluconazole5 Cisapride, terfenadine, astemizole, pimozide, quinidine, erythromycin, halofantrine, rifampicin, all-trans retinoid acid, alfentanil, amitriptyline/ nortriptyline, coumarin-type anticoagulants, short-acting benzodiazepines, carbamazepine, celecoxib, cyclophosphamide, fentanyl, ciclosporin, sirolimus, losartan, methadone, NSAIDs, phenytoin, prednisone, rifabutin, saquinavir, oral sulphonylureas, theophylline, voriconazole and zidovudine. Potential interaction with other drugs metabolised by CYP3A4 such as nifedipine, isradipine, amlodipine, verapamil and felodipine, ivacaftor, HMG CoA reductase inhibitors, everolimus, tacrolimus and vinca alkaloids

For more information please refer to the full Summary of Product Characteristics

NSAID, non-steroidal anti-inflammatory drug

*Interaction studies have been performed in adults1
ǂEither 9mg/ml (0.9%) sodium chloride for infusion or 50 mg/ml (5%) glucose for infusion.
† Infusion solution concentration is 0.77 mg/ml.
IV, intravenous; WFI, water for infusion

References


    1.     Ecalta® Summary of Product Characteristics.
    2.     Vazquez JA. Clin Ther 2005;27:657–673.
    3.     Cancidas (Formerly Caspofungin MSD) Summary of Product Characteristics.
    4.     Micafungin Summary of Product Characteristics.
    5.     Diflucan Summary of Product Characteristics.